loading...

Treatment Related Impact Measure for Diabetes (TRIM-D)

Novo Nordisk (Denmark)

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

The development process for the TRIM-Diabetes has been an iterative one, beginning in 2002.

Authors

Novo Nordisk (Denmark)

Copyright
TRIM-D © Novo Nordisk, August 2008.
Objective
To measure treatment related impact on subjects of diabetes medication and diabetes devices
Therapeutic area
  • Nutritional and Metabolic Diseases
  • Endocrine System Diseases
Therapeutic indication

Diabetes Mellitus

Type 1 – IDDM, Type 2 – Insulin-requiring patients
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Brod M, Hammer M, Christensen T, Lessard S, Bushnell DM. Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health Qual Life Outcomes. 2009 Sep 9;7:83 (Full Text Article)

Brod M, Christensen T, Hammer M, Busk AK, Bushnell DM. Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures. Qual Life Res. 2011 Nov;20(9):1513-8. Epub 2011 Mar 19 (Full Text article)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

Novo Nordisk (Denmark)

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

TRIM-D

Afrikaans for South Africa
Albanian for MACEDONIA*
Arabic for Algeria*
Arabic for Israel
Arabic for Kuwait*
Arabic for Saudi Arabia*
Arabic for the United Arab Emirates*
Assamese for India*
Bengali for India
Bosnian for Bosnia and Herzegovina*
Bulgarian for Bulgaria
Cebuano for the Philippines*
Chinese for Hong Kong
Chinese for Malaysia
Croatian for Bosnia*
Croatian for Croatia
Czech for Czech Republic*
Danish for Denmark
Dutch for Belgium (Flemish)
Dutch for the Netherlands*
English for Australia
English for Canada*
English for Hong Kong
English for India
English for Malaysia
English for South Africa
English for the Philippines*
English for the UK*
Estonian for Estonia*
Farsi for Iran
Filipino for the Philippines*
Finnish for Finland
French for Algeria*
French for Belgium
French for Canada*
French for France*
German for Austria
German for Germany*
German for Switzerland
Greek for Greece
Gujarati for India
Hebrew for Israel
Hiligaynon for the Philippines*
Hindi for India
Hungarian for Hungary*
Ilocano for the Philippines*
Italian for Italy*
Japanese for Japan
Kannada for India
Korean for South Korea
Latvian for Latvia*
Lithuanian for Lithuania*
Macedonian for Macedonia
Malay for Malaysia
Malayalam for India
Mandarin for China
Mandarin for Malaysia
Mandarin for Taiwan
Marathi for India
Norwegian for Norway
Oriya for India
Polish for Poland*
Portuguese for Brazil
Portuguese for Portugal
Punjabi for India
Romanian for Romania
Russian for Estonia*
Russian for Israel
Russian for Latvia*
Russian for Lithuania*
Russian for Russia*
Russian for Ukraine
Serbian for Bosnia*
Serbian for Serbia
Slovak for Slovakia
Slovenian for Slovenia
Sotho for South Africa*
Spanish for Argentina
Spanish for Chile*
Spanish for Mexico
Spanish for Peru*
Spanish for Spain*
Spanish for the USA*
Swedish for Finland
Swedish for Sweden
Tagalog for the Philippines*
Tamil for India
Tamil for Malaysia
Telugu for India
Thai for Thailand
Turkish for Turkey*
Ukrainian for Ukraine
Urdu for India*
Vietnamese for Vietnam*
Vietnamese for the USA*
Xhosa for South Africa*
Zulu for South Africa*
* Performed by Mapi

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

E-versions

Conditions to implement in electronic applications

Please refer to the "Contact and conditions of use" tab

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us